Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 7Completed 6Recruiting 5Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7Genitourinary 6Lymphoid 5Head & Neck 4Gynecologic 4Gastrointestinal 3Breast 3Sarcoma 2Other hematologic neoplasm 2Myeloid 2CNS 2Plasma cell 1Dermatologic 1Classical hematology 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Disulfides × Dermatologic × Clear all
NCT04676087 2024-08-13

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Emory University

Phase 1/2 Terminated
5 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡